Pregled bibliografske jedinice broj: 539012
Levels of dipeptidyl peptidase IV/CD26 substrates neuropeptide Y and vasoactive intestinal peptide in rheumatoid arthritis patients
Levels of dipeptidyl peptidase IV/CD26 substrates neuropeptide Y and vasoactive intestinal peptide in rheumatoid arthritis patients // Rheumatology international, 33 (2013), 11; 2867-2874 doi:10.1007/s00296-013-2823-z (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 539012 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Levels of dipeptidyl peptidase IV/CD26 substrates neuropeptide Y and vasoactive intestinal peptide in rheumatoid arthritis patients
Autori
Buljević, Sunčica ; Detel, Dijana ; Batičić Pucar, Lara ; Mihelić, Radovan ; Madarević, Tomislav ; Sestan, Branko ; Varljen, Jadranka
Izvornik
Rheumatology international (0172-8172) 33
(2013), 11;
2867-2874
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
dipeptidyl peptidase IV/CD26; neuropeptide Y; rheumatoid arthritis; vasoactive intestinal peptide
Sažetak
Neuropeptide Y (NPY) and vasoactive intestinal peptide (VIP) have their biological half-lives controlled by dipeptidyl peptidase IV (DPP IV/CD26). Several lines of evidence suggest the involvement of NPY in the regulation of rheumatoid arthritis (RA), and VIP has already been identified as a potent anti-inflammatory factor that reduces joint inflammation. The role of DPP IV/CD26 in the pathogenesis of RA has been indicated, but its mediator actions involving NPY and VIP have not been well investigated, so the aim of this study was to find an association between NPY, VIP, and DPP IV/CD26 in RA patients. Assessment of NPY, VIP, DPP IV/CD26 as well as some other inflammatory markers was carried out in 20 RA patients being treated with different types of drugs. Control group consisted of 18 osteoarthritis patients. Synovial fluid and serum content of investigated molecules was determined by ELISA and DPP IV/CD26 activity was measured spectrophotometrically. Immunodetection showed elevated levels of NPY and VIP in RA patients, with a significant increase in synovial fluid, while concentration and activity of DPP IV/CD26 were significantly decreased in both synovial fluid and serum. Positive correlations between serum DPP IV/CD26 concentration and activity (R = 0.6961), as well as between serum and synovial fluid concentration of VIP (R = 0.7029) were found. In RA group, NPY, VIP, and DPP IV/CD26 concentrations were not affected by the administration of drugs. The results of this study indicate a connection between elevated concentration of NPY and VIP and decreased DPP IV/CD26 activity and concentration, suggesting a potential role of these molecules in the immunomodulation of RA.
Izvorni jezik
Engleski
Znanstvena područja
Temeljne medicinske znanosti
POVEZANOST RADA
Projekti:
062-0061245-0213 - Uloga dipeptidil-peptidaze IV (CD26/DPP IV) u kroničnim bolestima (Varljen, Jadranka, MZOS ) ( CroRIS)
Ustanove:
Medicinski fakultet, Rijeka
Profili:
Tomislav Mađarević
(autor)
Sunčica Buljević
(autor)
Branko Šestan
(autor)
Lara Batičić
(autor)
Dijana Detel
(autor)
Radovan Mihelić
(autor)
Jadranka Varljen
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE